Hangzhou Chengyuan Genomics will provide single-cell analysis services and sell 1CellBio's InDrop instrument, reagents, and kits in China.
The system uses microfluidics and real-time image analysis to isolate single cells and provide visual documentation of monoclonality.
The device allows researchers to track cancer growth for a longer period of time, enabling improved observations and analysis, according to the researchers.
Ascendas will develop and commercialize molecular diagnostic systems and assays using certain of Fluidigm's microfluidic technologies.
New research has identified circulating cell subtypes with ties to better or worse outcomes in individuals with prostate cancer.
The Bay Area firm is planning to launch a low-cost, microfluidics-based infectious disease diagnostic called the Simple Chip in the next few years.
The company is providing several of its Parsortix instruments to the CANCER-ID consortium as part of an effort to establish liquid biopsy in routine clinical practice.
The company is preparing a blood-based test for early-stage pancreatic cancer that it hopes to have on the market by 2019.
The agency is sending an Oxford Nanopore MinIon to the International Space Station to determine if the technology's microfluidic system can work in microgravity.
The aim of the project, called Metafluidics, is to replace cumbersome conventional approaches with a cheaper, faster, and higher-throughput microfluidics platform.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.